TL;DR
Get beauty and skincare favorites delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
UK sales of hair-loss products grew 32% in the year to the end of August, according to Worldpanel by Numerator, as use of GLP-1 medicines also rose. A BMJ study identified an association between GLP-1 drugs and increased hair-loss risk, but researchers described the absolute risk as low; the source report says Novo Nordisk plans to enter the hair-loss treatment market.
UK sales of hair-loss products rose 32% in the year to the end of August, as household use of GLP-1 medicines increased, according to figures cited by Cosmetics Business. The report links the trends but does not establish that the medicines caused the sales growth; it also cites a BMJ study associating GLP-1 drugs with increased hair-loss risk and says Novo Nordisk plans to enter the hair-loss treatment market.
Worldpanel by Numerator data cited in the report put household use of GLP-1 medicines in Great Britain at 2.3% in 2024, rising to 4.1% in 2025 and 6.3% in 2026. The source does not provide the survey methodology or a more precise 2026 measurement date. The figures refer to households, not the share of individual people taking the medicines.
The report says the BMJ study found a link between GLP-1 drugs and a higher risk of hair loss, while researchers characterized the absolute risk as low. It does not supply the study’s participant numbers, risk estimates, medicines examined or proposed biological explanation, so those details cannot be assessed from the supplied material.
Worldpanel by Numerator also estimates that UK hair-loss product sales increased 32% over the year ending in late August. Cosmetics Business describes the rise as likely correlated with the growth in GLP-1 use. The figures show two trends occurring together; they do not establish why individual consumers bought the products or how much of the sales change is attributable to medication-related shedding.
Hair-Care Demand Meets GLP-1 Growth
The report points to a developing overlap between weight-management medicines and hair care. If some users experience hair loss, demand may grow for products marketed to thicken, strengthen or support hair. That could shape product development and marketing, as well as how shoppers evaluate claims about treatments.
For people taking or considering GLP-1 medicines, the reported association may be relevant to discussions about possible side effects. The source says the study found a low absolute risk, and it does not establish that a particular person’s hair loss was caused by a drug. Consumers should not treat the sales trend as medical evidence or change prescribed treatment based on product marketing; questions about side effects are best discussed with a qualified clinician.
The commercial response is also taking shape. The report says Novo Nordisk intends to enter the hair-loss treatment arena, a notable move by the maker of Ozempic. It gives no product, timing or regulatory details, so the statement signals interest rather than a treatment currently available through that plan.
Products Worth Considering
Therabody Theragun Mini 3rd Generation Massage Gun
Withings Body Scan Smart Scale with Segmental Body Composition and ECG, Black
Therabody Theragun Relief Massage Gun, 3-Speed, Black
As an affiliate, we earn on qualifying purchases.
From Anecdotes to Published Research
Hair products marketed for volume, thickness and strength, alongside products aimed at hair loss and thinning, existed before the current growth in GLP-1 use. The change described by Cosmetics Business is the increased attention and commercial demand associated with wider use of drugs such as semaglutide and tirzepatide.
The report says concerns about hair loss among GLP-1 users were initially anecdotal. It then points to a recent BMJ study as research identifying an association with increased risk. That distinction matters: anecdotes can prompt investigation, while an association in a study does not by itself prove that a medicine directly causes a side effect.
The market figures and study findings offer separate pieces of context. Worldpanel by Numerator’s household-use estimates describe the spread of GLP-1 medicines in Great Britain, while its sales estimate tracks hair-loss products in the UK. The report presents them together as evidence of a possible market connection, not as a controlled analysis demonstrating that rising prescriptions drove purchases.
“Household use of GLP-1 medicines in Great Britain rose from 2.3% in 2024 to 4.1% in 2025 and 6.3% in 2026.”
— Worldpanel by Numerator, as cited by Cosmetics Business
Cause, Risk and Product Plans
The supplied report does not provide enough information to quantify the study’s findings for an individual patient. Its description establishes that researchers identified an association and called the absolute risk low, but it does not show whether the risk varies by medicine, dose, duration of use or patient characteristics. The evidence provided here also does not establish a direct cause-and-effect relationship.
The sales increase cannot be assigned to GLP-1 use on the figures given. The report does not include consumer surveys explaining purchases, product-category definitions, sales values or a comparison group. Other reasons for buying hair-loss products are not explored in the supplied extract.
Novo Nordisk’s reported intention is also short on specifics. It is unclear whether the company plans to develop a medicine, acquire or partner with another business, or pursue another kind of treatment, and no launch date or regulatory filing is given.
Evidence and Commercial Details Ahead
Further details from the BMJ study would help readers understand the size and limits of the reported risk, including the medicines and populations examined and the absolute event rates. Until those details are available, the source supports describing a reported association, not a settled explanation for hair loss among GLP-1 users.
Market data over subsequent periods may show whether hair-loss product sales continue to rise, but sales figures alone cannot identify the reason. More detailed consumer research or analysis comparing use of GLP-1 medicines with product purchases would be needed to test the proposed connection.
Novo Nordisk’s next steps are not specified in the report. Any announcement identifying a treatment, development timeline or regulatory pathway would clarify what its stated interest means in practice. For now, the confirmed development in the supplied material is a reported intention to enter the category, alongside rising use and sales estimates.
Key Questions
What is the reported connection between GLP-1 medicines and hair loss?
The Cosmetics Business report says a BMJ study identified an association between GLP-1 drugs and increased hair-loss risk. Researchers reportedly described the absolute risk as low. The supplied material does not establish that the drugs directly cause hair loss in every affected person.
How much did UK hair-loss product sales increase?
Worldpanel by Numerator estimated that sales grew 32% in the year to the end of August. The report does not specify the sales value or demonstrate that GLP-1 use caused the increase.
How common is GLP-1 use in Great Britain?
The figures cited by Cosmetics Business put household use at 2.3% in 2024, 4.1% in 2025 and 6.3% in 2026. These are household figures, not the share of individuals using the medicines; the source extract does not give the methodology or exact 2026 period.
Is Novo Nordisk launching a hair-loss product?
The report says Novo Nordisk announced an intention to enter the hair-loss treatment market. It provides no product name, launch date, regulatory status or further details, so a specific product launch is not confirmed in the supplied material.
Source: cosmeticsbusiness.com
